bosentan anhydrous has been researched along with Acute Liver Injury, Drug-Induced in 37 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.70) | 18.2507 |
| 2000's | 4 (10.81) | 29.6817 |
| 2010's | 29 (78.38) | 24.3611 |
| 2020's | 3 (8.11) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Barber, J; Dawson, S; Kenna, JG; Paul, N; Stahl, S | 1 |
| Ding, D; Fang, H; Kelly, R; Liu, Z; Shi, Q; Tong, W | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Isomoto, H; Kimura, R; Sugihara, T; Sugita, K; Yamamoto, O | 1 |
| Bai, J; Fan, X; Hu, J; Hu, M; Li, Y; Sun, Y; Wang, B; Xu, Y; Zhao, S | 1 |
| Emoto, N; Hatae, T; Horibata, S; Kumagai, S; Nakayama, K; Suzuki, Y; Tsuji, G; Uemura, Y; Yorifuji, K | 1 |
| Chen, Y; Dunn, KW; Dunn, RT; Morgan, RE; Ryan, J; Volak, LP | 1 |
| Catalá-López, F; de la Fuente Honrubia, C; Macías Saint-Gerons, D; Montero Corominas, D | 1 |
| Bendjilali, N; De Marco, T; Halladay, J; Hsueh, WC; Khojasteh, C; Kobashigawa, EA; Kroetz, DL; Le, H; Markova, SM; McGlothlin, D; Mefford, J; Rettie, AE; Schwartz, JB; Sodhi, J; Witte, JS; Wu, AH; Zhang, C | 1 |
| Watkins, PB | 1 |
| Akpinar, E; Bayir, Y; Gocer, F; Halici, Z; Unal, B; Yayla, M | 1 |
| Ayaz, G; Baygutalp, NK; Bayir, Y; Calik, M; Demirci, E; Ferah, I; Gundogdu, C; Ozkanlar, S | 1 |
| Amuro, H; Ito, T; Nishizawa, T; Nomura, S; Ozaki, Y; Son, Y; Tamaki, T; Tanaka, A | 1 |
| Glukhova, SI; Iudkina, NN; Kurmukov, IA; Nasonov, EL; Nikolaeva, EV; Volkov, AV | 1 |
| Day, JS; Guan, Y; Guo, Y; Hillgren, KM; Michie, SA; Nishimura, S; Nishimura, T; Peltz, G; Takeda, ST; Wu, M; Xu, D; Yang, Z; Yates, AJ; Zheng, M | 1 |
| Andersson, LC; Bergare, J; Billger, M; Eakins, JA; Elebring, M; Elmore, CS; Foster, AJ; Kenna, JG; Stahl, SH; Thompson, RA | 1 |
| Aversa, M; Granton, J; Porter, S | 1 |
| Vinken, M | 1 |
| Bucher, J; Heinzle, E; Klein, S; Maggioni, S; Mauch, K; Mueller, D; Niklas, J; Noor, F; Shevchenko, V | 1 |
| Imawaka, H; Kaneko, N; Matsunaga, N; Nakanishi, T; Nunoya, K; Staub, AY; Tamai, I | 1 |
| Dwyer, N; Jones, G; Kilpatrick, D | 1 |
| Bambara, LM; Biasi, D; Caramaschi, P; Mahamid, H | 1 |
| Corris, PA; Langleben, D | 1 |
| Eriksson, C; Gustavsson, A; Kronvall, T; Tysk, C | 1 |
| Hasegawa, M; Hattori, T; Ishikawa, O; Nagai, Y; Okada, E; Tago, O | 1 |
| Varga, J | 1 |
| Girgis, RE; Hassoun, PM; Krishnan, JA; Mathai, SC; Wigley, FM | 1 |
| McIntyre, K | 1 |
| Bauer, C; Diekmann, F; Hocher, B; Lutz, J; Slowinski, T; Thöne-Reineke, C; Zart, R | 1 |
5 review(s) available for bosentan anhydrous and Acute Liver Injury, Drug-Induced
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Hepatotoxicity in patients treated with endothelin receptor antagonists: systematic review and meta-analysis of randomized clinical trials].
Topics: Antihypertensive Agents; Biomarkers; Bosentan; Chemical and Drug Induced Liver Injury; Endothelin Receptor Antagonists; Humans; Hypertension; Isoxazoles; Phenylpropionates; Pyridazines; Randomized Controlled Trials as Topic; Safety-Based Drug Withdrawals; Sulfonamides; Thiophenes; Transaminases | 2014 |
Comparative safety and tolerability of endothelin receptor antagonists in pulmonary arterial hypertension.
Topics: Animals; Antihypertensive Agents; Bosentan; Chemical and Drug Induced Liver Injury; Drug Interactions; Drug Monitoring; Endothelin Receptor Antagonists; Heart Failure; Humans; Hypertension, Pulmonary; Phenylpropionates; Pyridazines; Pyrimidines; Risk; Sulfonamides | 2015 |
Adverse Outcome Pathways and Drug-Induced Liver Injury Testing.
Topics: Bosentan; Chemical and Drug Induced Liver Injury; Cholestasis; Fatty Liver; Humans; Liver Cirrhosis; Methotrexate; Quantitative Structure-Activity Relationship; Sulfonamides; Valproic Acid | 2015 |
Hepatotoxicity by bosentan in a patient with portopulmonary hypertension: a case-report and review of the literature.
Topics: Adult; Antihypertensive Agents; Bosentan; Chemical and Drug Induced Liver Injury; Female; Humans; Hypertension, Portal; Hypertension, Pulmonary; Sulfonamides | 2011 |
2 trial(s) available for bosentan anhydrous and Acute Liver Injury, Drug-Induced
| Article | Year |
|---|---|
[Bosentan: a considerable increase in the survival of patients with pulmonary hypertension associated with systemic rheumatic diseases].
Topics: Antihypertensive Agents; Bosentan; Chemical and Drug Induced Liver Injury; Disease Progression; Dose-Response Relationship, Drug; Drug Monitoring; Drug Therapy, Combination; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Kaplan-Meier Estimate; Lupus Erythematosus, Systemic; Male; Middle Aged; Scleroderma, Systemic; Sulfonamides; Survival Rate; Treatment Outcome | 2014 |
New hope for systemic sclerosis patients with digital ulcers.
Topics: Administration, Oral; Bosentan; Chemical and Drug Induced Liver Injury; Double-Blind Method; Endothelin Receptor Antagonists; Fingers; Foot Dermatoses; Hand Dermatoses; Humans; Scleroderma, Localized; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Toes; Treatment Outcome | 2005 |
30 other study(ies) available for bosentan anhydrous and Acute Liver Injury, Drug-Induced
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Cholestasis; Drug-Related Side Effects and Adverse Reactions; Humans; Insecta; Rats; Risk Factors | 2012 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Models, Biological; Predictive Value of Tests | 2011 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
Treatment of Digital Ulcers and Reflux Oesophagitis in a Patient with Systemic Sclerosis: Increased Risk of Hepatotoxicity due to a Potential Drug-drug Interaction Between Bosentan and Vonoprazan.
Topics: Bosentan; Chemical and Drug Induced Liver Injury; Drug Interactions; Esophagitis, Peptic; Humans; Pharmaceutical Preparations; Pyrroles; Scleroderma, Systemic; Sulfonamides; Ulcer | 2021 |
Drug interaction study of flavonoids toward OATP1B1 and their 3D structure activity relationship analysis for predicting hepatoprotective effects.
Topics: Animals; Bosentan; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Flavonoids; Food-Drug Interactions; HEK293 Cells; Herb-Drug Interactions; Humans; Liver; Liver-Specific Organic Anion Transporter 1; Male; Methotrexate; Molecular Conformation; Organic Anion Transporters; Rats, Sprague-Dawley; Structure-Activity Relationship | 2020 |
Predictive model of bosentan-induced liver toxicity in Japanese patients with pulmonary arterial hypertension.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Bosentan; Carbohydrate Sulfotransferases; Chemical and Drug Induced Liver Injury; Creatinine; Endothelin Receptor Antagonists; Female; Humans; Japan; Liver; Male; Models, Statistical; Mutation; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Predictive Value of Tests; Pulmonary Arterial Hypertension; Risk Assessment; Sulfotransferases | 2020 |
Intravital Multiphoton Microscopy with Fluorescent Bile Salts in Rats as an In Vivo Biomarker for Hepatobiliary Transport Inhibition.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; Bile; Bile Acids and Salts; Biological Transport; Biomarkers; Bosentan; Chemical and Drug Induced Liver Injury; Fluorescent Dyes; Hepatocytes; Liver; Male; Microscopy; Phenylacetates; Rats; Rats, Wistar; Sulfonamides | 2018 |
Association of CYP2C9*2 with bosentan-induced liver injury.
Topics: Alanine Transaminase; Aryl Hydrocarbon Hydroxylases; Aspartate Aminotransferases; Bosentan; Chemical and Drug Induced Liver Injury; Cytochrome P-450 CYP2C9; Endothelin Receptor Antagonists; Female; Genetic Association Studies; Genetic Markers; HEK293 Cells; Humans; Hypertension, Pulmonary; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Organic Anion Transporters; Polymorphism, Single Nucleotide; Sulfonamides | 2013 |
Managing the risk of drug-induced liver injury.
Topics: Aryl Hydrocarbon Hydroxylases; Bosentan; Chemical and Drug Induced Liver Injury; Cytochrome P-450 CYP2C9; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Male; Sulfonamides | 2013 |
Protective effect of Et-1 receptor antagonist bosentan on paracetamol induced acute liver toxicity in rats.
Topics: Acetaminophen; Alanine Transaminase; Animals; Antioxidants; Aspartate Aminotransferases; Bosentan; Chemical and Drug Induced Liver Injury; Cytoprotection; Dose-Response Relationship, Drug; Endothelin Receptor Antagonists; Endothelin-1; Female; Liver; Oxidative Stress; Rats; Receptors, Endothelin; Sulfonamides; Tumor Necrosis Factor-alpha | 2014 |
Endothelin receptor inhibition with bosentan delays onset of liver injury in streptozotocin-induced diabetic condition.
Topics: Animals; Bosentan; Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Experimental; Endothelin Receptor Antagonists; Endothelin-1; Gene Expression Regulation; Glutathione; Liver; Male; Malondialdehyde; Rats; Streptozocin; Sulfonamides; Superoxide Dismutase; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha | 2015 |
Combined use of ursodeoxycholic acid and bosentan prevents liver toxicity caused by endothelin receptor antagonist bosentan monotherapy: two case reports.
Topics: Aged; Bosentan; Chemical and Drug Induced Liver Injury; Cholagogues and Choleretics; Drug Therapy, Combination; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Liver Function Tests; Middle Aged; Sulfonamides; Ursodeoxycholic Acid | 2014 |
Chimeric TK-NOG mice: a predictive model for cholestatic human liver toxicity.
Topics: Animals; Bosentan; Cefmetazole; Chemical and Drug Induced Liver Injury; Cholestasis; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Ganciclovir; Hepatocytes; Humans; Metabolic Clearance Rate; Mice, Transgenic; Species Specificity; Sulfonamides; Thymidine Kinase; Tissue Distribution; Transgenes | 2015 |
Multiple compound-related adverse properties contribute to liver injury caused by endothelin receptor antagonists.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Bosentan; Cell Line; Cell Survival; Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Endothelin Receptor Antagonists; Epithelial Cells; Hepatocytes; Humans; Isoxazoles; Mitochondria; Molecular Structure; Oxygen Consumption; Phenylpropionates; Pyridazines; Sulfonamides; Thiophenes | 2015 |
In Silico Modeling for the Prediction of Dose and Pathway-Related Adverse Effects in Humans From In Vitro Repeated-Dose Studies.
Topics: Bosentan; Cell Line, Tumor; Chemical and Drug Induced Liver Injury; Computer Simulation; Dose-Response Relationship, Drug; Humans; Sulfonamides; Toxicity Tests; Valproic Acid | 2016 |
Analysis of the Metabolic Pathway of Bosentan and of the Cytotoxicity of Bosentan Metabolites Based on a Quantitative Modeling of Metabolism and Transport in Sandwich-Cultured Human Hepatocytes.
Topics: Biological Transport; Biotransformation; Bosentan; Cell Culture Techniques; Cell Survival; Cells, Cultured; Chemical and Drug Induced Liver Injury; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2C9 Inhibitors; Endothelin Receptor Antagonists; Female; Hepatocytes; Humans; Hydroxylation; Kinetics; Male; Microsomes, Liver; Models, Biological; Pyrimidines; Sulfonamides | 2016 |
Severe hepatotoxicity in a patient on bosentan upon addition of methotrexate: reversible with resumption of methotrexate without bosentan.
Topics: Antihypertensive Agents; Bosentan; Chemical and Drug Induced Liver Injury; Dermatologic Agents; Drug Interactions; Female; Humans; Hypertension, Pulmonary; Methotrexate; Middle Aged; Polypharmacy; Scleroderma, Systemic; Sulfonamides | 2009 |
Liver impairment after concomitant administration of bosentan and clarithromycin in systemic sclerosis.
Topics: Aged; Anti-Bacterial Agents; Antihypertensive Agents; Bosentan; Chemical and Drug Induced Liver Injury; Clarithromycin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fingers; Humans; Hypertension, Pulmonary; Liver Function Tests; Middle Aged; Scleroderma, Systemic; Skin Ulcer; Sulfonamides | 2010 |
The Achilles heel of endothelin receptor therapy for pulmonary arterial hypertension.
Topics: Bosentan; Chemical and Drug Induced Liver Injury; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Isoxazoles; Liver; Phenotype; Receptors, Endothelin; Sulfonamides; Thiophenes | 2010 |
Bosentan for digital ulcers in patients with systemic sclerosis.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Chemical and Drug Induced Liver Injury; Female; Hand Dermatoses; Humans; Male; Middle Aged; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Treatment Outcome; Young Adult | 2012 |
Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Chemical and Drug Induced Liver Injury; Exercise Tolerance; Female; Follow-Up Studies; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Middle Aged; Recovery of Function; Scleroderma, Systemic; Sulfonamides; Survival Analysis; Time Factors; Treatment Outcome | 2005 |
Drug-related hepatotoxicity.
Topics: Antihypertensive Agents; Bosentan; Chemical and Drug Induced Liver Injury; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Sulfonamides; Transaminases | 2006 |
Role of the paracrine liver endothelin system in the pathogenesis of CCl4-induced liver injury.
Topics: Animals; Bosentan; Carbon Tetrachloride Poisoning; Chemical and Drug Induced Liver Injury; Endothelin Receptor Antagonists; Endothelins; Liver; Liver Diseases; Liver Function Tests; Male; Rats; Rats, Inbred WKY; Sulfonamides | 1995 |